Phathom Pharmaceuticals Inc

NASDAQ:PHAT   3:59:53 PM EDT
33.02
+1.15 (+3.61%)
Products

Phathom Submits 2 NDAs To U.S. FDA For Vonoprazan-Based Treatment Regimens For H. Pylori Infection

Published: 09/08/2021 12:37 GMT
Phathom Pharmaceuticals Inc (PHAT) - Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. Pylori Infection.
Phathom Pharmaceuticals Inc - If Approved, Anticipate Launch in U.S. in Second Half of 2022.